- Home
- INM vs DRMA Comparison
INM vs DRMA Comparison
Compare INM & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INM
- DRMA
- Stock Information
- Founded
- INM 1981
- DRMA 2014
- Country
- INM Canada
- DRMA United States
- Employees
- INM N/A
- DRMA N/A
- Industry
- INM Biotechnology: Pharmaceutical Preparations
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- INM Health Care
- DRMA Health Care
- Exchange
- INM Nasdaq
- DRMA Nasdaq
- Market Cap
- INM 4.3M
- DRMA 3.6M
- IPO Year
- INM N/A
- DRMA 2021
- Fundamental
- Price
- INM $2.36
- DRMA $5.58
- Analyst Decision
- INM
- DRMA Strong Buy
- Analyst Count
- INM 0
- DRMA 1
- Target Price
- INM N/A
- DRMA $10.00
- AVG Volume (30 Days)
- INM 47.0K
- DRMA 37.9K
- Earning Date
- INM 11-13-2025
- DRMA 11-12-2025
- Dividend Yield
- INM N/A
- DRMA N/A
- EPS Growth
- INM N/A
- DRMA N/A
- EPS
- INM N/A
- DRMA N/A
- Revenue
- INM $4,920,990.00
- DRMA N/A
- Revenue This Year
- INM N/A
- DRMA N/A
- Revenue Next Year
- INM N/A
- DRMA N/A
- P/E Ratio
- INM N/A
- DRMA N/A
- Revenue Growth
- INM N/A
- DRMA N/A
- 52 Week Low
- INM $1.72
- DRMA $5.04
- 52 Week High
- INM $8.27
- DRMA $23.80
- Technical
- Relative Strength Index (RSI)
- INM 56.86
- DRMA 47.40
- Support Level
- INM $2.11
- DRMA $5.27
- Resistance Level
- INM $2.28
- DRMA $6.23
- Average True Range (ATR)
- INM 0.11
- DRMA 0.40
- MACD
- INM 0.03
- DRMA 0.07
- Stochastic Oscillator
- INM 78.57
- DRMA 45.52
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.